On the other hand, a 2024 study led by University of Pennsylvania psychologist Thomas A. Wadden, PhDand funded by Novo Nordisk, the maker of semaglutidefound that GLP-1 takers without known psychopathology werent any more likely to develop depression or suicidal thoughts or actions than controls.
In adults, GLP-1RAs induced significant reductions in the depression rating scales compared to control treatments. GLP-1RAs alleviate depressive symptoms in Type 2 diabetes patients. When only RCTs were included, GLP-1RAs showed a significant positive effect on depressive symptoms in adults.
This particular example perfectly highlights why Glp-1 Therapy And Depression is so captivating.
Notably, patients on GLP-1 RAs exhibited a 195% higher risk of major depression, a 108% increased risk for anxiety, and a 106% elevated risk for suicidal behavior.
GLP-1 RAs show promise as treatment for depression through multiple neuromodulatory mechanisms. While there is strong preclinical evidence, observational results are mixed, and clinical findings are still preliminary.
 "Image result for GLP-1 therapy and depression")
 "Image result for GLP-1 therapy and depression")
